liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
Karolinska Institutet.
Karolinska Institutet.
Karolinska Institutet.
Karolinska Institutet.
Show others and affiliations
2011 (English)In: Multiple Sclerosis, ISSN 1352-4585, E-ISSN 1477-0970, Vol. 17, no 6, 708-719 p.Article in journal (Refereed) Published
Abstract [en]

Background: A post marketing surveillance study was conducted to evaluate safety and efficacy of natalizumab in Swedish multiple sclerosis (MS) patients since its introduction in August 2006 until March 2010. Methods: Patients were registered in the web-based Swedish MS-registry at 40 locations and evaluated every 6 months. Adverse events and clinical outcomes were recorded. Results: One thousand one hundred and fifty-two patients were included (71.4% female) and 149 patients stopped treatment; the main reason was planned pregnancy. Anti-natalizumab antibodies were found in 4.5% (52 patients) of which 1.6% displayed persistent antibodies. Serious adverse events were rare, but included three cases with progressive multifocal leukoencephalopathy (PML). There were seven fatal cases, probably unrelated to the natalizumab treatment. For relapsing-remitting MS patients (n = 901), mean Expanded Disability Status Scale (EDSS, -10.7%), Multiple Sclerosis Severity Scale (MSSS, -20.4%), Multiple Sclerosis Impact Scale (MSIS-29, physical -9.9%, psychological -13.3%) and Symbol Digit Modalities Test (SDMT, +10.7%) all showed significant improvements during 24 months of treatment with natalizumab. The Swedish web-based MS quality registry proved to function as a platform for post-marketing MS drug surveillance, providing long-term data regarding drug effects and adverse events beyond clinical trials. Conclusions: Our results indicate that natalizumab is generally well tolerated and has sustained efficacy for patients with active MS, though the risk of PML is still an important concern.

Place, publisher, year, edition, pages
SAGE Publications , 2011. Vol. 17, no 6, 708-719 p.
Keyword [en]
disease-modifying therapies; multiple sclerosis; relapsing-remitting; Tysabri
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-69885DOI: 10.1177/1352458510394701ISI: 000291729000009OAI: diva2:433312
Available from: 2011-08-09 Created: 2011-08-08 Last updated: 2012-03-23

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Dahle, Charlotte
By organisation
Clinical ImmunologyFaculty of Health SciencesDepartment of Clinical Immunology and Transfusion Medicine
In the same journal
Multiple Sclerosis
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 57 hits
ReferencesLink to record
Permanent link

Direct link